Leerink Partnrs Issues Optimistic Forecast for CRBU Earnings

Key Points

• Leerink Partners raised their FY2025 earnings estimate for Caribou Biosciences to ($1.57) per share from a previous estimate of ($1.64).
• Shares of Caribou Biosciences increased by 1.3%, trading at $2.03 with a notable market cap of $188.66 million.
• Caribou's latest earnings report showed a loss of ($0.35) EPS for the quarter, which was better than the consensus estimate of ($0.40).

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 earnings estimates for Caribou Biosciences in a research report issued to clients and investors on Tuesday, August 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.57) for the year, up from their previous estimate of ($1.64). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.73) EPS, FY2027 earnings at ($1.82) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($0.81) EPS.

CRBU has been the topic of several other reports. HC Wainwright restated a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Wall Street Zen cut shares of Caribou Biosciences from a "hold" rating to a "sell" rating in a report on Saturday.

Caribou Biosciences Stock Down 5.6%

Shares of CRBU traded down $0.11 during mid-day trading on Friday, hitting $1.87. The stock had a trading volume of 1,374,212 shares, compared to its average volume of 1,613,636. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The company has a market cap of $174.13 million, a PE ratio of -1.05 and a beta of 2.55. The company's fifty day simple moving average is $1.68 and its two-hundred day simple moving average is $1.25.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%. The firm had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million.

Institutional Trading of Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CRBU. Next Capital Management LLC bought a new stake in Caribou Biosciences in the second quarter valued at $25,000. Creative Planning acquired a new stake in shares of Caribou Biosciences in the 2nd quarter worth about $25,000. Hudson Bay Capital Management LP bought a new stake in Caribou Biosciences in the 2nd quarter valued at about $30,000. Russell Investments Group Ltd. boosted its stake in Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after purchasing an additional 21,416 shares during the period. Finally, MetLife Investment Management LLC grew its position in Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after purchasing an additional 9,148 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.